ATLANTA (GenomeWeb) – When researchers from Progenetica-Hermes Pardini Institute in Brazil screened a dozen patients using a next-generation sequencing-based gene panel test they developed, they uncovered a number of variants of unknown significance (VUS), one of the investigators said at the American Association for Clinical Chemistry annual meeting here yesterday.

Giovana Torrezan and her Progenetica colleagues screened a dozen women lacking BRCA1 or BRCA2 mutations for other breast cancer-linked mutations to find that eight of them harbored VUS.

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.